Day 2Wednesday, September 2, 2026 - UTC+08:00

• Delving into the transformative potential of nucleic acid-based therapies and enabling technologies, with insights into APAC’s unique investment opportunities, including emerging biotech hubs, innovative startups, and regional strengths in clinical trials and manufacturing

• Exploring collaborative investment strategies to accelerate development pipelines and expand market access for nucleic acid technologies across APAC.

• Examining the evolving regulatory frameworks for nucleic acid therapeutics across Asia-Pacific and Western regions, with a focus on harmonizing standards to support global innovation and accessibility.

• Discussing challenges and opportunities in navigating diverse regulatory landscapes, including strategies for accelerating approvals and ensuring safety and efficacy in emerging RNA-based treatments.

• Using genetically targeted mouse studies, thiomorpholino oligonucleotides (TMOs) have focused on DMD, NPC, DIPG, STAT3, and Type ll Diabetes with results superior to other chemistries.

• In various cell culture experiments using TMOs to target exon skipping or RNase H activation, significant biological activity focused on genes such as FUS, SLC6A1, ITGA4, PKM, PEG10, Psoriasis, RDEB, and others has been demonstrated.

• Recently TMOs have shown activity in experiments focused on siRNAs and CRISPER/CAS experiments.

• Developing a scalable cell-derived nanoparticle platform for RNA delivery to the brain
• In preclinical animal studies, the platform showed functional RNA delivery to over 70% of neurons following a single IV injection

Highlighting the future innovation potential of RNA therapeutics, focusing on next-generation approaches such as RNA editing, non-coding RNAs, and circular RNAs (circRNAs) to address complex diseases and advance precision medicine in Asia- Pacific